clonidine has been researched along with Hyperesthesia in 3 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Hyperesthesia: Increased sensitivity to cutaneous stimulation due to a diminished threshold or an increased response to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment, but not posttreatment, with intrathecal clonidine significantly delayed the development of thermal hyperesthesia in a dose-dependent manner, and this delay in onset produced by clonidine was 3 days after the nerve injury." | 7.69 | Clonidine, but not morphine, delays the development of thermal hyperesthesia induced by sciatic nerve constriction injury in the rat. ( Nozaki-Taguchi, N; Yamamoto, T, 1996) |
| "Pretreatment, but not posttreatment, with intrathecal clonidine significantly delayed the development of thermal hyperesthesia in a dose-dependent manner, and this delay in onset produced by clonidine was 3 days after the nerve injury." | 3.69 | Clonidine, but not morphine, delays the development of thermal hyperesthesia induced by sciatic nerve constriction injury in the rat. ( Nozaki-Taguchi, N; Yamamoto, T, 1996) |
| "The spinal mechanism of the phantom pain origin is proved." | 1.28 | [Pathogenesis of phantom limb syndrome and its treatment]. ( Gurchin, FA; Kirsanova, GV; Naryshkin, AG; Samoĭlov, KA; Shvets, IaM; Vasilevskaia, LS, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, T | 1 |
| Nozaki-Taguchi, N | 1 |
| Jevtovic-Todorovic, V | 1 |
| Wozniak, DF | 1 |
| Powell, S | 1 |
| Nardi, A | 1 |
| Olney, JW | 1 |
| Naryshkin, AG | 1 |
| Gurchin, FA | 1 |
| Samoĭlov, KA | 1 |
| Kirsanova, GV | 1 |
| Vasilevskaia, LS | 1 |
| Shvets, IaM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
3 other studies available for clonidine and Hyperesthesia
| Article | Year |
|---|---|
Clonidine, but not morphine, delays the development of thermal hyperesthesia induced by sciatic nerve constriction injury in the rat.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Clonidine; Disease Models, Animal; | 1996 |
Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Clonidine; Dizocilpine Maleate; Dose-Respo | 1998 |
[Pathogenesis of phantom limb syndrome and its treatment].
Topics: Adult; Aged; Amputation Stumps; Arm; Baclofen; Clonidine; Drug Therapy, Combination; Female; Humans; | 1989 |